Eisai's Halaven can offer significant overall survival benefit in rare soft tissue sarcoma subtypes
New Phase III data has shown Halaven (eribulin) from Japanese pharma major Eisai (TYO: 4523) can offer a significant overall survival benefit in rare soft tissue sarcomas compared to dacarbazine.
Halaven offers a survival benefit of 13.5 months in advanced leiomyosarcoma (LMS) and 11.5 months for adipocytic sarcoma compared to dacarbazine. It has a toxicity profile consistent with prior experience, and there were no unexpected or new safety findings.
Another study showed that women with metastatic breast cancer treated with an eribulin/capecitabine combination had an overall response rate of 42.9% and a median progression-free survival of 7.1 months. This confirms the safety and efficacy of the dose-combination of eribulin and capecitabine 1000mg/m2 twice daily.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze